Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selwyn J Hurwitz

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Antiviral Research|October 9, 2002
Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Antiviral Research|August 31, 2011
In silico study supports the efficacy of a reduced dose regimen for stavudineSelwyn J Hurwitz, Raymond F Schinazi
Current Opinion in HIV and AIDS|October 9, 2013
Prodrug strategies for improved efficacy of nucleoside antiviral inhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Drug Discovery Today. Technologies|April 5, 2013
Practical Considerations For Developing Nucleoside Reverse Transcriptase InhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Journal of Clinical Microbiology|July 5, 2003
Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptaseViktoria Nurpeisov, Selwyn J Hurwitz, Prem L Sharma
Antiviral Chemistry & Chemotherapy|March 7, 2008
Development of a population simulation model for HIV monotherapy virological outcomes using lamivudineSelwyn J Hurwitz, Ghazia Asif, Raymond F Schinazi
Antiviral Chemistry & Chemotherapy|May 14, 2005
Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humansSelwyn J Hurwitz, Michael J Otto, Raymond F Schinazi
Antiviral Research|May 24, 2006
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency virusesRaymond F Schinazi, Brenda I Hernandez-Santiago, Selwyn J Hurwitz
Antimicrobial Agents and Chemotherapy|October 8, 2008
Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation modelSelwyn J Hurwitz, Ghazia Asif, Nancy M Kivel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 11, 2009
Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assayEmilie Fromentin, Ghazia Asif, Aleksandr Obikhod, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Antiviral Research|October 9, 2002
Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Antiviral Research|August 31, 2011
In silico study supports the efficacy of a reduced dose regimen for stavudineSelwyn J Hurwitz, Raymond F Schinazi
Current Opinion in HIV and AIDS|October 9, 2013
Prodrug strategies for improved efficacy of nucleoside antiviral inhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Drug Discovery Today. Technologies|April 5, 2013
Practical Considerations For Developing Nucleoside Reverse Transcriptase InhibitorsSelwyn J Hurwitz, Raymond F Schinazi
Journal of Clinical Microbiology|July 5, 2003
Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptaseViktoria Nurpeisov, Selwyn J Hurwitz, Prem L Sharma
Antiviral Chemistry & Chemotherapy|March 7, 2008
Development of a population simulation model for HIV monotherapy virological outcomes using lamivudineSelwyn J Hurwitz, Ghazia Asif, Raymond F Schinazi
Antiviral Chemistry & Chemotherapy|May 14, 2005
Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humansSelwyn J Hurwitz, Michael J Otto, Raymond F Schinazi
Antiviral Research|May 24, 2006
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency virusesRaymond F Schinazi, Brenda I Hernandez-Santiago, Selwyn J Hurwitz
Antimicrobial Agents and Chemotherapy|October 8, 2008
Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation modelSelwyn J Hurwitz, Ghazia Asif, Nancy M Kivel, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 11, 2009
Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assayEmilie Fromentin, Ghazia Asif, Aleksandr Obikhod, et al.
Pageof 5